Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 18;5:23. doi: 10.1038/s41541-020-0173-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Mice were immunized intramuscularly with 100 ng Pfs230C1 admixed with CoPoP/PHAD liposomes (400 ng PHAD) and 15 and 1 μg of Pfs230C1 with Alum on day 0 and 21. a Comparison of IgG titer between day 42 (n = 10 mice) and day 250 (n = 5 mice). (b) Antibody kinetics for Alum (15 ug Pfs230C1) and CoPoP/PHAD (50 ng Pfs230C1). Geometric mean and 95% confidence interval of groups (n = 5 mice) are shown. (c) LMR to EU in feeder (square root scale) with day 250 IgGs. Each dot represents purified IgG from n = 10 mice. The asterisk shows the same best-fit line using day 42 CoPoP/PHAD data shown in Fig. 4c. (d) IgG subclass percentage of indicated adjuvants with different amount of Pfs230C1. (e) avidity of indicated adjuvants with different amount of Pfs230C1, each dot represents purified IgG from n = 10 mice. For a, the titer comparison between Day 42 and Day250 with indicated adjuvants, log10-transformed titer were analyzed by Student's t test.